Participants who took tirzepatide (Zepbound) dropped an average of 50 pounds over 72 weeks. Those who took semaglutide ...

Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

Eli Lilly’s Zepbound led to 47% greater weight loss than Wegovy in a 72-week trial, yet retail sentiment turned bearish on ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...